Phase II clinical trials of Oxford COVID-19 vaccine begin in Chennai & Pune

▴ Phase II clinical trials of Oxford COVID-19 vaccine begin in Chennai & Pune
After, Covishield's first shot, tests related to COVID-19 and antibodies came negative, officials said

Second Phase clinical trials of Oxford COVID-19 vaccine begin in Chennai and Pune. In Chennai, two prominent medical institutions are starting the second and third phase field trial of the Oxford vaccine candidate Covishield.

In another development, the Tamil Nadu Government has exempted college students having arrears except in the last semester from writing the examinations, in view of Covid-19. Previously the exemption has been made for the regular students.

Meanwhile, the total number of COVID-19 infections in the state is nearing the four lakh mark. 5958 people were tested positive yesterday taking the total to over 3,97000. However, the active caseload in the state is about 52 thousand.

Chennai is one of the seventeen locations in India to conduct the field trial of the promising vaccine candidate Covishield, developed jointly by the Oxford University and AstraZeneca. The Government Rajiv Gandhi General Hospital and the Sri Ramachandra Institute of Higher Education and Research are the two institutions in the city that run the trial.

The state director of public health Dr TS Selva Vinayagam, who coordinates the study in Chennai, told , healthy volunteers above the age of 18 are being involved in its multi-centric clinical trial. Dr TS Selva Vinayagam, Director, Public Health said, “We will be starting the Phase-2 and Phase-3 together. We will be following the volunteers for up to 180 days. This is to assess the safety, immunogenicity and reacto-genecity. We will be doing that.” The T-cells in the white blood corpuscles against the viral pathogen are said to be observed in 14-days after administering the vaccine and the antibodies in about 28 days. Their effectiveness to eliminate the virus and several other factors will be exhaustively tested during the trial.In Maharashtra, the Phase II clinical trial of the Oxford COVID-19 vaccine, being manufactured by the Serum Institute of India (SII), began at a medical college and hospital in Pune today. According to the Hospital officials, two male volunteers were administered the vaccine at Bharati Vidyapeeth's Medical College and Hospital post noon today.

Our correspondent reports, doctors at Bharati Vidyapeeth's Medical College and Hospital administered the first shot of the 'Covishield' vaccine to a 32-year-old man after his reports of COVID-19 and antibodies tests came out negative. Another 48-year-old male volunteer was also given the vaccine. According to details by the Medical Director of Bharati Vidyapeeth's Medical College Hospital and Research Centre, Dr Sanjay Lalwani, the COVID-19 and antibodies tests were conducted on the five volunteers.

Of them, the reports of three volunteers' antibodies test came out positive so they became ineligible for today's trial. The doctor informed that in all, 25 candidates will be given the vaccine in next seven days. Meanwhile, the Sangli district administration has initiated stringent action on the private hospitals which are asking to deposit advanced amount before admitting Covid positive patients. The Sangli district collector, Dr. Abhijit Choudhari said that the private hospitals cannot ask a patient to deposit advanced amount before his admission to the hospital.

Tags : #Covishield #OxfordVaccine #SerumInstitute #Pune #Chennai #Phase2trialCovidvaccine #OxfordVaccinePhase2Trial #CovishieldPhase2Trial #Astrazeneca #LatestCovidNewsAug27

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Transforming Brain Healthcare: India's Visionary Task Force for Neurological DisordersApril 25, 2024
The Battle Against Malaria: Rising Trends and Vaccine InnovationsApril 25, 2024
Talc and Asbestos Controversy: Inside Johnson & Johnson's Courtroom StruggleApril 25, 2024
The Hidden Struggles of Parenthood: Addressing Isolation, Loneliness, and BurnoutApril 25, 2024
FDA Confirms Bird Flu Virus Remnants in Pasteurized Milk: Safety and Regulatory InsightsApril 24, 2024
Sarvodaya Hospital Redefines Total Knee Replacement Surgery with Augmented Reality April 23, 2024
Fateh Education announces partnership to expand educational opportunities for Indian studentsApril 23, 2024
10 Strategies to counter disinformation for the healthcare digital ecosystemApril 23, 2024
Is Selling Over-the-Counter (OTC) Drugs in General Stores A Step Towards Affordable Healthcare in IndiaApril 23, 2024
Student Health Crisis: Food Poisoning Incident Strikes Pune Coaching CentreApril 23, 2024
The Impact of Diabetes on Kidney Health: Diabetic Nephropathy ExplainedApril 23, 2024
Toddler Hospitalized After Consuming Expired Chocolates: Health Concerns RaisedApril 23, 2024
After months of diagnostic delay, a migrant worker could access TB services only when a community health worker met himApril 22, 2024
Indian Spices Contaminated with Cancer-Causing Chemical: Hong Kong Food Regulators Issue WarningApril 22, 2024
FTCCI organised a Workshop on Rooftop Kitchen GardeningApril 20, 2024
Children in Cities Exposed to Elevated Lead Levels: Study Reveals Urgent Health ConcernApril 20, 2024
Biocon Ventures into Weight-Loss Drug Market with Semaglutide DevelopmentApril 20, 2024
Innovative AI Assistance Empowers Moscow Doctors to Detect Cervical Spine Issues through MRI ScansApril 20, 2024
Air India Express ties up with AISATS for AeroWash Automated Aircraft Exterior Cleanings April 19, 2024
IndoSup raises strategic funding led by CCI group promoters Naresh Sharma and Satish Sharma; investors include Yatra.com’s Rohan Mittal April 19, 2024